Evotec SE (WBO:EVT) Total Current Assets : €903.2 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Evotec SE's total current assets for the quarter that ended in Dec. 2023 was €903.2 Mil.

Evotec SE Total Current Assets Historical Data

The historical data trend for Evotec SE's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Total Current Assets Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

469.53

658.84

1,100.94

1,073.67

903.16

Evotec SE Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															1,095.82	1,073.67	1,026.45	939.20	903.16

Evotec SE Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Evotec SE's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	616.871	+	204.055	+	30.89	+	51.346
	=	903.2

Evotec SE's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	616.871	+	204.055	+	30.89	+	51.346
	=	903.2

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Evotec SE (WBO:EVT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Evotec SE's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	616.871	-	1132.561	+	0.75 * 98.396	+	0.5 * 30.89
=	-426.4

Evotec SE Total Current Assets Related Terms

Thank you for viewing the detailed overview of Evotec SE's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (WBO:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines

From GuruFocus

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023